{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IL-15", "query": { "intervention": "IL-15" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 141, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IL-15&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T21:01:25.220Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05867420", "title": "A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "ASKG915", "type": "BIOLOGICAL" }, { "name": "Paclitaxel + Bevacizumab", "type": "DRUG" }, { "name": "Fruquintinib", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "AskGene Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 594, "start_date": "2023-08-02", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-01-27", "last_synced_at": "2026-09-02T21:01:25.220Z", "location_count": 2, "location_summary": "New York, New York • Pittsburgh, Pennsylvania", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05867420" }, { "nct_id": "NCT07574541", "title": "Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma", "Prostate Cancer", "Neoplasms", "Carcinoma", "Neoplasms, Glandular and Epithelial", "Neoplasms by Histologic Type" ], "interventions": [ { "name": "TriAdeno vaccine", "type": "BIOLOGICAL" }, { "name": "N-803", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "MALE", "summary": "18 Years to 120 Years · Male only" }, "enrollment_count": 52, "start_date": "2026-09-07", "completion_date": "2028-06-15", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-02T21:01:25.220Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07574541" }, { "nct_id": "NCT03586869", "title": "QUILT-3.080: NANT Pancreatic Cancer Vaccine", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Aldoxorubicin HCl", "type": "DRUG" }, { "name": "ALT-803", "type": "BIOLOGICAL" }, { "name": "ETBX-011", "type": "BIOLOGICAL" }, { "name": "ETBX-021", "type": "BIOLOGICAL" }, { "name": "ETBX-051", "type": "BIOLOGICAL" }, { "name": "ETBX-061", "type": "BIOLOGICAL" }, { "name": "GI-4000", "type": "BIOLOGICAL" }, { "name": "GI-6207", "type": "BIOLOGICAL" }, { "name": "GI-6301", "type": "BIOLOGICAL" }, { "name": "haNK for infusion", "type": "BIOLOGICAL" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "nab-Paclitaxel", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Avelumab", "type": "BIOLOGICAL" }, { "name": "SBRT", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2018-07-17", "completion_date": "2019-08-01", "has_results": true, "last_update_posted_date": "2024-08-27", "last_synced_at": "2026-09-02T21:01:25.220Z", "location_count": 1, "location_summary": "El Segundo, California", "locations": [ { "city": "El Segundo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03586869" }, { "nct_id": "NCT06198296", "title": "Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatoblastoma", "Hepatocellular Carcinoma", "Wilms Tumor", "Malignant Rhabdoid Tumor", "Yolk Sac Tumor", "Rhabdomyosarcoma", "Liposarcoma", "Embryonal Sarcoma of Liver" ], "interventions": [ { "name": "21.15.GPC3-CAR T cells", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 21, "start_date": "2025-06-10", "completion_date": "2043-02-01", "has_results": false, "last_update_posted_date": "2025-11-03", "last_synced_at": "2026-09-02T21:01:25.220Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06198296" }, { "nct_id": "NCT03387085", "title": "QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Aldoxorubicin HCl", "type": "DRUG" }, { "name": "N-803", "type": "BIOLOGICAL" }, { "name": "ETBX-011", "type": "BIOLOGICAL" }, { "name": "ETBX-051", "type": "BIOLOGICAL" }, { "name": "ETBX-061", "type": "BIOLOGICAL" }, { "name": "GI-4000", "type": "BIOLOGICAL" }, { "name": "GI-6207", "type": "BIOLOGICAL" }, { "name": "GI-6301", "type": "BIOLOGICAL" }, { "name": "haNK for Infusion", "type": "BIOLOGICAL" }, { "name": "avelumab", "type": "BIOLOGICAL" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "nab-Paclitaxel", "type": "DRUG" }, { "name": "SBRT", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2018-03-19", "completion_date": "2024-01-16", "has_results": true, "last_update_posted_date": "2024-08-09", "last_synced_at": "2026-09-02T21:01:25.220Z", "location_count": 1, "location_summary": "El Segundo, California", "locations": [ { "city": "El Segundo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03387085" }, { "nct_id": "NCT02191098", "title": "Proof of Principle Study of Pulse Dosing of IL-15 to Deplete the Reservoir in HIV Infected People", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV", "Stable ART" ], "interventions": [ { "name": "ALT-803", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 10, "start_date": "2015-06", "completion_date": "2019-09-09", "has_results": false, "last_update_posted_date": "2020-01-27", "last_synced_at": "2026-09-02T21:01:25.220Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02191098" }, { "nct_id": "NCT05020678", "title": "NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Non-Hodgkin", "B-cell Acute Lymphoblastic Leukemia", "Large B-cell Lymphoma", "Mantle Cell Lymphoma", "Indolent Lymphoma", "Waldenstrom Macroglobulinemia", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Aggressive Lymphoma", "Large-cell Lymphoma" ], "interventions": [ { "name": "NKX019", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Nkarta, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2021-08-20", "completion_date": "2038-12", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-09-02T21:01:25.220Z", "location_count": 2, "location_summary": "Denver, Colorado • Cleveland, Ohio", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05020678" }, { "nct_id": "NCT04377932", "title": "Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Liver Cancer", "Rhabdomyosarcoma", "Malignant Rhabdoid Tumor", "Liposarcoma", "Wilms Tumor", "Yolk Sac Tumor" ], "interventions": [ { "name": "AGAR T cells", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 14, "start_date": "2021-08-08", "completion_date": "2040-08-26", "has_results": true, "last_update_posted_date": "2026-01-21", "last_synced_at": "2026-09-02T21:01:25.220Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04377932" }, { "nct_id": "NCT05700630", "title": "Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-1-infection", "ART", "Cd4+ Lymphocyte Deficiency", "Lymphoid Tissue; Infection", "Interleukin" ], "interventions": [ { "name": "FT538", "type": "BIOLOGICAL" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2024-07-15", "completion_date": "2024-08-21", "has_results": false, "last_update_posted_date": "2024-02-26", "last_synced_at": "2026-09-02T21:01:25.220Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05700630" }, { "nct_id": "NCT03136406", "title": "QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "avelumab", "type": "BIOLOGICAL" }, { "name": "ALT-803", "type": "BIOLOGICAL" }, { "name": "aNK for Infusion", "type": "BIOLOGICAL" }, { "name": "ETBX-011", "type": "BIOLOGICAL" }, { "name": "GI-4000", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2017-08-11", "completion_date": "2019-11-01", "has_results": true, "last_update_posted_date": "2024-06-11", "last_synced_at": "2026-09-02T21:01:25.220Z", "location_count": 1, "location_summary": "El Segundo, California", "locations": [ { "city": "El Segundo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03136406" } ] }